Results 181 to 190 of about 44,049 (225)

Aquagenic Pruritus Questionnaire: Predicting Myeloproliferative Neoplasms in Patients with Aquagenic Pruritus. [PDF]

Dermatol Ther (Heidelb)
Witte F, Weisshaar E, Metz M, Koschmieder S, Isfort S, Kremer AE, Griesshammer M, Royeck S, Ständer S, Zeidler C.   +9 more
europepmc   +1 more source

JAK2V617F reprograms Hypoxia Inducible Factor-1 to induce a non-canonical hypoxia regulon in myeloproliferative neoplasms. [PDF]

Leukemia
Kealy D, Ellerington R, Bansal S, Medeiros JJF, Hawley CA, Zeng AGX, Lukaszonek J, West KA, Sinha AD, Caalim G, Gawne RT, Pope J, Ferreira BL, Blacknell NM, Drylie B, Chatzigerou J, Khoo HM, Wilkinson AC, Fielding AK, Wang G, Psaila B, Kent DG, Hitchcock IS, Holding AN, Mason AS, Gupta V, Dick JE, Bridge KS.   +27 more
europepmc   +1 more source

Ruxolitinib and Hydroxycarbamide Are the Most Efficient Drugs to Reduce Aquagenic Pruritus Intensity in a Real-Word Cohort of Patients With Myeloproliferative Neoplasms. [PDF]

EJHaem
Gall-Ianotto CL, Civi L, Pan-Petesch B, Herbreteau L, Rio L, Lambert WC, Misery L, Lippert E, Ianotto JC.   +8 more
europepmc   +1 more source

Statins enhance the efficacy of pegylated interferon-alfa2 in Philadelphia-negative chronic myeloproliferative neoplasms. [PDF]

Blood Adv
Davidsen ID, Larsen MK, Löffler L, Skov V, Kjær L, Knudsen TA, Sørensen AL, Christensen SF, Cordua S, Eickhardt-Dalbøge CS, Kristiansen MH, Ellervik C, Wienecke T, Hasselbalch HC.   +13 more
europepmc   +1 more source

Predicting modelling for early diagnosis in early myeloproliferative neoplasms, not otherwise specified. Evidence from a machine learning study. [PDF]

Front Oncol
Scattone A, Lupo A, Saponaro C, Sonnessa M, Ditonno P, Bove S, Fanizzi A, Accogli G, Daprile R, Zito FA, Comes MC, Massafra R.   +11 more
europepmc   +1 more source

Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms. [PDF]

J Immunother Cancer
Pesini C, Gil-Bellido M, S Millan L, Oñate C, Calvo-Pérez A, Santiago L, Iglesias E, Bernal JP, Araujo-Voces M, Paz Artigas L, García-Martínez L, Roig FJ, Movilla Meno N, Garcia-Aznar JM, Menéndez-Jandula B, Olave MT, Azaceta Reinares G, Garrote M, Alvarez-Larrán A, Gálvez EM, Sánchez Martínez D, Arias MA, Pardo J, Ramirez-Labrada A.   +23 more
europepmc   +1 more source

Challenges in the Evolving Role of Calreticulin as a Promising Target for Precision Medicine in Myeloproliferative Neoplasms. [PDF]

Cancers (Basel)
Costa A, Breccia M.
europepmc   +1 more source

Non-invasive detection of bone marrow fibrosis in myeloproliferative neoplasms using cell-free RNA. [PDF]

iScience
Saad M, Fuchs SNR, Schalla C, Götz K, Pritchard JE, Flosdorf N, Benabid A, Gleitz HFE, Leimkühler N, Dugourd A, Schneider RK.   +10 more
europepmc   +1 more source

Second malignancies among older patients with classical myeloproliferative neoplasms treated with ruxolitinib. [PDF]

Blood Neoplasia
Wang R, Stempel JM, Shallis RM, Huntington SF, Zeidan AM, Neparidze N, Di M, Bewersdorf JP, Mendez L, Ma X, Podoltsev NA.   +10 more
europepmc   +1 more source